Ready for New HIV Challenges in Post-ART Era?

In 90’s the introduction of antiretroviral therapy for HIV treatment changed gradually HIV infection in a chronic disease. The consolidated use of highly active antiretroviral treatment (HAART)substantially affect HIV RNA plasma viremia levels, leading circulating virus below the current analytical cut off limits, and, in the major part of cases, to CD4+ T cells recovery. However, it is not ableto eliminate HIV-1, which persists as a latent infection in anatomical and functional reservoirs, such as resting memory CD4+ T cells. Moreover, HAART is unable to reduce or clock the persistent immune dysfunction, inflammation and coagulation abnormalities, which are commonly observed in HAART-treated patients and that are strongly predictors of risk for non-AIDS morbidity and mortality.

Edelweiss Journal of AIDS welcomes submissions related to HIV, STIs, Infection, Immunity and not restricted to given fields. Authors may submit their valuable work at: editor@edelweisspublications.com